お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
970812

下肢静止不能症候群市場:2020~2026年

Restless Legs Syndrome Market 2020-2026

出版日: | 発行: Orion Market Research Pvt Ltd | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.58円
下肢静止不能症候群市場:2020~2026年
出版日: 2020年10月19日
発行: Orion Market Research Pvt Ltd
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の下肢静止不能症候群の市場規模は、予測期間中に6.2%のCAGRで拡大すると予測されています。下肢静止不能症候群(RLS)の有病率の増加は、市場の成長を担う重要な要因です。 RLSは、糖尿病、パーキンソン病、腎不全、腎疾患などの慢性疾患が原因で発生します。したがって、これらの疾患の高い有病率は、RLSの治療のためのデバイスの需要を創出し、ひいては同市場の成長を促進すると予想されます。

下肢静止不能症候群市場は、種類別、治療法別、およびエンドユーザー別に分類されます。タイプ別では、市場は一次下肢静止不能症候群、二次下肢静止不能症候群に細分化されます。治療法別では、市場は投薬、治療、デバイスに分類されます。エンドユーザー別では、市場は病院、在宅医療、その他に分類されます。病院は、より高いライフサイクル、病院内の医療機器の効率化のため、エンドユーザー市場でかなりのセグメントになると予測されています。

地理的に市場は北米、欧州、アジア太平洋、およびその他の地域に分類されます。北米は、下肢静止不能症候群の治療に利用可能な治療法に関連する患者の意識が高いため、下肢静止不能症候群市場で大きなシェアを占めています。さらに、国の高度なヘルスケアシステムは、下肢静止不能症候群の治療に使用されるデバイスと治療法の成長をサポートしています。アジア太平洋地域は、予測期間中にかなりの市場シェアを保持すると予想されます。

Pfizer、Inc.、GlaxoSmithKline plc、Boehringer Ingelheim GmbH、Teva Pharmaceutical Industries Ltd.、Mylan NV、Glenmark Pharmaceuticals Ltd.などは、世界の下肢静止不能症候群市場で活動している主要企業です。新製品の発売と製品開発は、これらの主要な市場プレーヤーの中心的なテーマです。さらに、下肢静止不能症候群市場の主要なプレーヤーは、市場シェアを拡大するために有機的または無機的市場活動を積極的に採用しています。

当レポートでは、世界の下肢静止不能症候群市場について調査し、市場の概要とともに、種類別、治療法別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
  • 規則と規制

第3章 競合情勢

  • 企業シェア分析
  • 重要な戦略分析
  • 主要企業分析
    • GlaxoSmithKline plc
    • Pfizer, Inc.
    • Boehringer Ingelheim GmbH
    • Teva Pharmaceutical Industries, Ltd.
    • UCB SA

第4章 市場の決定要因

  • 動機
  • 抑制要因
  • 市場機会

第5章 市場細分化

  • 世界の下肢静止不能症候群市場:治療法別
    • 投薬
    • 治療
    • デバイス
  • 世界の下肢静止不能症候群市場:エンドユーザー別
    • 病院
    • 在宅医療
    • その他

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • その他
  • その他

第7章 企業プロファイル

  • Akorn, Inc.
  • Arbor Pharmaceuticals, LLC
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Jazz Pharmaceuticals plc
  • Kyowa Hakko Kirin Co. Ltd.
  • LGM Pharma
  • Mallinckrodt Pharmaceuticals
  • Merck Co, Inc.
  • Mylan N.V.
  • Pfizer, Inc.
  • Serina Therapeutics, Inc.
  • Teva Pharmaceutical Industries, Ltd.
  • UCB S.A.
図表

LIST OF TABLES

  • 1. GLOBAL RESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 2. GLOBAL RESTLESS LEGS SYNDROME MEDICATION MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL RESTLESS LEGS SYNDROME THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL RESTLESS LEGS SYNDROME DEVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL RESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 6. GLOBAL HOSPITALS FOR RESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL HOMECARES FOR RESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL RESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 10. NORTH AMERICAN RESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 11. NORTH AMERICAN RESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 12. NORTH AMERICANRESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 13. EUROPEAN RESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 14. EUROPEANRESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 15. EUROPEANRESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 16. ASIA-PACIFIC RESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 17. ASIA-PACIFIC RESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 18. ASIA-PACIFICRESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
  • 19. REST OF THE WORLDRESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 20. REST OF THE WORLDRESTLESS LEGS SYNDROME MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL RESTLESS LEGS SYNDROME MARKET SHARE BY TREATMENT, 2019 VS 2026 (%)
  • 2. GLOBAL RESTLESS LEGS SYNDROME MARKET SHARE BY END-USER, 2019 VS 2026 (%)
  • 3. GLOBAL RESTLESS LEGS SYNDROME MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 4. THE US RESTLESS LEG SYNDROME MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA RESTLESS LEG SYNDROME MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD RESTLESS LEG SYNDROMEMARKET SIZE, 2019-2026 ($ MILLION)
目次
Product Code: OMR2022577

Global Restless Legs Syndrome Market Size, Share & Trends Analysis Report by Type (Primary Restless Legs Syndrome, Secondary Restless Legs Syndrome), by Treatment (Medication, Therapy, Devices), by End-User (Hospitals, Homecare, Others) Forecast Period 2020-2026

The global restless legs syndrome market is projected to grow at a CAGR of 6.2% during the forecast period. The increase in the prevalence of restless legs syndrome is a key factor responsible for the growth of the market. RLS occurs due to chronic diseases such as diabetes, Parkinson's disease, kidney failure, or renal diseases. Therefore, the high prevalence of the diseases is anticipated to create the demand for devices for the treatment of RLS which in turn will drive the market growth.

The restless leg syndrome market is segmented based on type, treatment, and end-users. Based on type the market is sub-segmented into primary restless legs syndrome, secondary restless legs syndrome. Based on treatment, the market is segmented into Medication, Therapy, Devices. Based on end-user, the market is segmented into hospitals, home care, and others. Hospital is forecast to be the considerable segment in the end-user market owing to the higher lifecycle, better efficiency of the medical equipment in the hospitals.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America holds the major share in the Restless Leg Syndrome market due to the higher awareness among the patients related to the available treatments for the treatment of restless legs syndrome. Further, the advanced healthcare system in the country has supported the growth of the devices and therapies that are used in the treatment of the restless legs syndrome. Asia-Pacific is anticipated to hold considerable market share during the forecast period.

Pfizer, Inc., GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Glenmark Pharmaceuticals Ltd., and so on are the key players operating in the global restless legs syndrome market. The new product launch and product development are the core focus of these major market players. Moreover, the key players of the Restless Leg Syndrome market are actively adopting organic or inorganic market activities to increase their market share.

Research Methodology

The market study of the global restless leg syndrome market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.

Whitepapers, research-papers, and news blogs.

Company websites and their product catalog.

The report is intended for healthcare companies, hospitals, clinics, and other related companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Restless Leg Syndrome Market Research and Analysis by Treatment

2. Global Restless Leg Syndrome Market Research and Analysis by End-User

The Report Covers:

Comprehensive research methodology of the global restless leg syndrome market.

This report also includes a detailed and extensive market overview with key analyst insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the global restless leg syndrome market.

Insights about market determinants which are stimulating the global restless leg syndrome market.

Detailed and extensive market segments with regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. GlaxoSmithKline plc
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Pfizer, Inc.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Boehringer Ingelheim GmbH
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Teva Pharmaceutical Industries, Ltd.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. UCB SA
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Restless Leg SyndromeMarket by Treatment
    • 5.1.1. Medication
    • 5.1.2. Therapy
    • 5.1.3. Devices
  • 5.2. Global Restless Legs Syndrome Market by End-User
    • 5.2.1. Hospitals
    • 5.2.2. Homecare
    • 5.2.3. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. US
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Akorn, Inc.
  • 7.2. Arbor Pharmaceuticals, LLC
  • 7.3. Boehringer Ingelheim GmbH
  • 7.4. GlaxoSmithKline plc
  • 7.5. Glenmark Pharmaceuticals Ltd.
  • 7.6. Jazz Pharmaceuticals plc
  • 7.7. Kyowa Hakko Kirin Co. Ltd.
  • 7.8. LGM Pharma
  • 7.9. Mallinckrodt Pharmaceuticals
  • 7.10. Merck Co, Inc.
  • 7.11. Mylan N.V.
  • 7.12. Pfizer, Inc.
  • 7.13. Serina Therapeutics, Inc.
  • 7.14. Teva Pharmaceutical Industries, Ltd.
  • 7.15. UCB S.A.
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.